Orgenesis reports Q1 EPS (29c) vs (87c) last year

Reports Q1 revenue $141,000 vs $142,000 last year. Vered Caplan, CEO of Orgenesis, said, “We continue to advance the commercialization of our decentralized platform through Octomera, our strategic CGT processing subsidiary, including our Orgenesis Mobile Processing Units and Labs (OMPULs). OMPULs offer a rapid, standardized industrial cleanroom alternative at or near the point of care, which can be rapidly deployed and scaled at a significantly lower cost than centralized production. Importantly, we recently regained 100% ownership of Octomera in a strategic transaction, which not only provides us full control over this subsidiary as we roll out these services to global customers, but also supports the development of our own proprietary therapeutic pipeline, including our immune-oncology portfolio. We believe the combination of our breakthrough therapies, coupled with our decentralized production of CGTs, have positioned Orgenesis to transform the industry by enabling the production of life-saving therapies in a fraction of the time and at much lower cost.”